204 results about "Diabetic mouse" patented technology

The invention provides a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function and application thereof, and belongs to the technical field of functional microorganisms. The invention relates to a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function. The preservation number of the bifidobacterium animalis subsp. Lactis strain B21247 is GDMCC No: 65075. The strain B21247 has a good intestinal colonization function, and has the activity of inhibiting alpha-glucosidase in vitro. Meanwhile, a type 2 diabetes mouse model is used as an experimental model to verify that the strain B21247 achieves the effect of reducing blood sugar by adjusting glycosylated hemoglobin, reducing pancreatic beta cell damage and increasing secretion of intestinal GLP-1, and a new thought is provided for reducing blood sugar or treating diabetes.

The invention relates to a bifidobacterium animalis subsp. Lactis YYSJ001 with a blood sugar reducing effect and application of the bifidobacterium animalis subsp. Lactis YYSJ001. The classification name of the strain is bifidobacterium animalis subsp. Lactis, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.33471. The invention further relates to a preparation method of the bifidobacterium animalis subsp. Lactis YYSJ001. The bacterial strain has good artificial gastric juice resistance, artificial intestinal juice resistance and intestinal tract adhesion ability, has an inhibition effect on numerous pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella, klebsiella pneumoniae and quail chicken enterococcus, and can stimulate intestinal cells to generate glucagon-like peptide-1, so that the bacterial strain can be applied to preparation of various pathogenic bacteria. Diseases of diabetic mice can be effectively improved, and the compound can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.

The invention relates to a lactic acid bacterium capable of reducing fat, resisting inflammation and reducing blood sugar, which is classified and named as pediococcus acidilactici XJ335, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30093, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can achieve the fat reducing effect by adjusting the abundance of intestinal flora; the levels of IL-6 and TNF-alpha in serum of diabetic mice are remarkably improved through regulation, so that the anti-inflammatory effect is achieved; various cardiovascular diseases of atherosclerosis are prevented by adjusting the levels of TC, TG, HDL-C and LDL-C; by reducing FINS and HOMA-IR levels and improving HOMA-IS, HOMA-beta and QUICKI value levels, insulin resistance of a body is reduced, insulin sensitivity and pancreas islet beta cell functions of the body are improved, gene expression related to blood sugar regulation is regulated, and an excellent blood sugar reducing effect is achieved in the body.

The invention belongs to the technical field of biological medicines, and particularly relates to application of 1, 3-propane diamine or pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating diabetes. Experimental results show that 1, 3-propane diamine can obviously improve random blood glucose and fasting blood glucose of mice with type 2 diabetes mellitus, and 1, 3-propane diamine can obviously improve insulin resistance of model mice. According to the application, 1, 3-propane diamine is used for improving the blood sugar of patients with type 2 diabetes for the first time, an ideal treatment effect is achieved, a new treatment choice is provided for improving the blood sugar level through clinical application of 1, 3-propane diamine, and the application has extremely high application value and social benefits.

The invention provides an application of cichorium glandulosum polysaccharide in preparation, basic characterization and type 2 diabetes mellitus relieving medicines, and belongs to the technical field of medicines. Animal experiment results show that after the cichorium glandulosum polysaccharide is applied to type 2 diabetic mice, serum biochemical indexes can be adjusted, the blood sugar level can be reduced, organ injuries can be protected or repaired, and PI3K / AKT / mTOR signal channel related protein expression in the main glycometabolism target organ liver can be adjusted. Therefore, the prepared cichorium glandulosum polysaccharide can be used as a medicine for relieving type 2 diabetes mellitus.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving liver injury and regulating glycolipid metabolism and application of the bifidobacterium animalis subsp. Lactis. The preservation number of the bifidobacterium animalis subsp. Lactis is CGMCC No.31656, and the bifidobacterium animalis subsp. Lactis can effectively reduce blood sugar and blood fat of diabetic mice and relieve insulin resistance and has the capacity of relieving diabetic cardiomyopathy. The strain has wide application prospects in preparation of drugs for treating diabetes mellitus, liver injury and glycolipid metabolism.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus mucus fermentation TY-M26 and application of the lactobacillus mucus fermentation TY-M26, and the preservation number of the lactobacillus mucus fermentation TY-M26 is CGMCC (China General Microbiological Culture Collection Center) No. 32238. The lactobacillus mucilaginosus TY-M26 has high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus mucilaginosus TY-M26 can significantly relieve diabetes characteristics of mice with type II diabetes, significantly reduce fasting blood-glucose level, significantly improve insulin resistance and serum insulin level, significantly reduce serum Glu level and serum TG level, and can be used for preparing medicines for treating diabetes mellitus. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus mucilaginosus TY-M26 has the advantages that the lactobacillus mucilaginosus TY-M26 can be used for preparing the lactobacillus mucilaginosus TY-M26, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus

The invention belongs to the technical field of medicines, and particularly relates to application of indole-3-lactic acid in preparation of medicines for treating diabetes and complications. A db / db mouse is utilized to simulate the pathological process of human diabetes, the db / db mouse is orally administered with indole-3-lactic acid, and after the db / db mouse orally administered with indole-3-lactic acid, the blood glucose and blood fat of the diabetic mouse can be reduced, the cardiac function impairment of the diabetic mouse is improved, and the brain cognitive dysfunction of the diabetic mouse is improved. It is proved that the indole-3-lactic acid has a treatment effect on diabetes and cardiovascular and cerebrovascular complications thereof.

The invention discloses double-network hydrogel based on chlorogenic acid as well as a preparation method and application of the double-network hydrogel, and belongs to the technical field of wound dressings. A first network of the double-network hydrogel based on the chlorogenic acid is formed by coordination of the chlorogenic acid and Zn < 2 + >, and CA and Zn < 2 + > can be quickly released in inflammation and proliferation stages, so that the effects of resisting bacteria, resisting oxidation, diminishing inflammation and generating blood vessels are achieved; the second network is formed by covalent crosslinking of heparin grafted gelatin and genipin, crosslinking of gelatin and genipin can enhance the mechanical strength, heparin is grafted into gelatin, bFGF can be stably added, the release time of bFGF at a wound part can be prolonged, and bFGF is slowly released in proliferation and remodeling stages, so that scars are prevented from being formed; in-vivo studies of MRSA infected diabetic mouse models and rabbit ear hyperplastic scar models show that the dual-network hydrogel can significantly promote healing of scar-free wounds. The programmed release function of the CZGF hydrogel plays a key role in accelerating chronic wound healing and preventing scar formation.

The invention belongs to the field of biological medicine, and particularly relates to application of forsythiaside A in preparation of a medicine for relieving or treating diabetic cardiomyopathy. The forsythiaside A relieves or treats diabetic cardiomyopathy by regulating NLRP3 activation induced by endoplasmic reticulum stress. The forsythiaside A can reduce the levels of BG, GSP, TG, LDH, CK-MB, cTnI, MDA, IL-1beta, IL-6 and TNF-alpha of STZ induced diabetic mice, and meanwhile, the levels of IN and SOD are increased. The forsythiaside A can be used for reducing the expression levels of IL-1beta, IL-6, TNF-alpha, GRP78, TXNIP and NLRP3 in H9c2 cells induced by Glu. Therefore, forsythiaside A can induce NLRP3 inflammasome activation through endoplasmic reticulum stress to relieve diabetic cardiomyopathy, and a theoretical basis is provided for treating diabetic cardiomyopathy.

According to the preparation method and application of the single-cell probiotic coating disclosed by the invention, the coating is used for encapsulating lactobacillus plantarum YJ7 layer by layer by using a metal-phenol network and a chitosan-casein phosphopeptide compound, so that LP-coated TP / Fe < 3 + >-coated CPC is successfully constructed. The functional coating can effectively resist invasion of severe physiological environments of gastrointestinal tracts in vivo and in vitro under the condition that normal activity of LP is not affected, and the survival rate of the functional coating in intestinal tracts is greatly improved. A mouse in-vivo safety research shows that the hydrogel has excellent biocompatibility and harmlessness. In addition, gavage experiments on mice with type 2 diabetes prove that the delivery system enhances the hypoglycemic activity of the lactobacillus plantarum YJ7. In conclusion, the oral probiotic delivery system provides a simple and efficient strategy for enhancing the survival of the probiotics in the severe intestinal environment, and is expected to provide a new view angle for beneficial effects of the probiotics in the intestinal tract.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The present invention discloses a polyporus badius polysaccharide and its preparation method and application, belonging to the technical field of polysaccharide extraction. The polyporus badius polysaccharide (PPP-0A) includes galactose, fucose, glucose, mannose and xylose, and the molar ratios are 62.26%, 16.96%, 15.23%, 4.68% and 0.87% respectively. The present invention uses techniques such as methylation, scanning electron microscopy, thermogravimetric analysis, nuclear magnetic resonance and atomic force microscopy to determine the structural characteristics of PPP-0A, analyze its composition and properties, and its inhibitory effects on the activities of α-glucosidase and α-amylase. In addition, an in vitro HepG2 cell model induced by high blood glucose and high insulin levels was used to study the hypoglycemic effect of PPP-0A. The present invention provides a theoretical basis for clarifying the relationship between the hypoglycemic activity of PPP-0A and its hypoglycemic effect on type 2 diabetic mice.

The invention relates to application of lactobacillus acidophilus LA85 in preparation of a product with a blood sugar reducing effect. The brand new application of the lactobacillus acidophilus LA85 strain is developed, namely the lactobacillus acidophilus LA85 strain is used for inhibiting alpha-glucosidase, reducing blood sugar and improving diabetes mellitus, and tests prove that the food intake, the water intake and the urine volume of a mouse with type II diabetes mellitus can be effectively controlled after intervention of the LA85 strain, and the weight value of the mouse is stabilized; the glucose absorption and metabolism capability of diabetic mice is effectively improved, and continuous damage of pancreatic beta cell functions is retarded; the blood lipid level disorder state of the mouse with the type II diabetes mellitus is improved; the inflammation level of a mouse body with type II diabetes mellitus is reduced, and the immunity is improved; and a very good improvement and recovery effect is achieved on abundance and diversity reduction of intestinal flora of the type II diabetes mellitus mice.

The invention relates to mulberry oligosaccharide, a preparation method thereof and application of the mulberry oligosaccharide in blood sugar regulation and control. The mulberry oligosaccharide is obtained by processing mulberries through a large number of researches and specific process steps of enzymolysis, selenic acid modification, plasma treatment and the like, so that the stability of the mulberry oligosaccharide can be obviously improved, the inhibition capability on alpha-glucosidase is obviously improved, the sugar tolerance condition of diabetic mice is improved, the blood sugar level is stabilized, and the application prospect is wide. Meanwhile, the insulin sensitivity of the body can be improved, the insulin resistance degree can be improved, the absorption and utilization of insulin to glucose can be improved, the SOD activity of the body can be improved, and the MDA content can be reduced, so that the development of diabetes can be effectively slowed down. In addition, natural mulberry is used as a main preparation raw material, no harmful chemical component is added, the cost is low, the safety is good, and great social significance is achieved.

The invention relates to application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for assisting in improving diabetes mellitus. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The brand new application of the BLa80 strain of the animal bifidobacterium subsp. Lactis is developed, that is, the BLa80 strain is used for improving diabetes, reducing blood sugar or inhibiting alpha-glucosidase, and tests prove that the BLa80 strain can effectively control the food intake, the water intake, the urine volume and the body weight of diabetic mice; the fasting blood-glucose value and the insulin resistance index of a diabetic mouse are reduced; the blood lipid level disorder state of diabetic mice can be improved; the inflammation level of a diabetic mouse body is reduced, anti-inflammatory factors of the mouse body are increased, and the immunity is improved; and the abundance and diversity of intestinal flora of diabetic mice can be improved and recovered.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

The invention relates to the technical field of biological medicines, in particular to a Chinese wolfberry all-component mixture and application thereof in treatment of diabetes mellitus. The Chinese wolfberry all-component mixture is prepared through the following steps: S1, taking Chinese wolfberry fruits, performing continuous extraction for three times, combining extracting solutions obtained by the three times of extraction, performing filtration, and performing concentration so as to obtain a Chinese wolfberry fruit extract; s2, taking leaf buds, carpopodium and branches of the Chinese wolfberry, performing continuous extraction for three times, combining the three extraction solutions, filtering, and concentrating to obtain a leaf bud / carpopodium / branch extract of the Chinese wolfberry; and S3, mixing the Chinese wolfberry fruit extract obtained in the step S1 with the Chinese wolfberry leaf bud / fruit stem / branch extract obtained in the step S2, filtering, performing graded purification by adopting an ultrafiltration method, intercepting 20-100kDa components, and sterilizing to obtain a Chinese wolfberry all-component mixture. The Chinese wolfberry all-component mixture disclosed by the invention can be used for remarkably reducing a plurality of biochemical index levels such as fasting blood-glucose, glycosylated hemoglobin, triglyceride and extremely low density lipoprotein of a mouse with type 2 diabetes mellitus.

The invention discloses a method for constructing a diabetes animal model after hyperlipidemia type acute pancreatitis. The method comprises the following steps: S1, selecting male C57BL / 6N mice which are 7 weeks old, and feeding the male C57BL / 6N mice with hyperlipidemia; s2, injecting froglein into the abdominal cavity of the hyperlipemia mouse; s3, replacing drinking water of the mice with 5% sweet water, and testing fasting blood glucose and random blood glucose on the first day, the fourth day and the seventh day after the rain frog element is injected; s4, when the random blood glucose of the mouse is larger than or equal to 16.7 mmol / L or the fasting blood glucose of the mouse is larger than or equal to 11.1 mmol / L, the mouse And S5, killing the mouse with cervical vertebra dislocation, taking pancreatic tissues of the mouse, fixing the pancreatic tissues, performing HE staining, and if an acinus structure is damaged, cells are swelled and necrotic and a large number of inflammatory cells of interstitial substances are infiltrated, judging that the acute pancreatitis is molded. Meanwhile, if the conditions are met, it can be judged that the mouse is a diabetic mouse after hyperlipidemia type acute pancreatitis. The method can simulate the occurrence of diabetes mellitus after hyperlipemia type acute pancreatitis, and lays a good foundation for the research of diabetes mellitus after hyperlipemia type acute pancreatitis.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The invention relates to the field of biological medicine, and discloses application of an acellular fat extract in preparation of a medicine for accelerating chronic wound healing. Researches show that CEFFE can improve healing of chronic wounds of diabetic mice. This is achieved by the pro-angiogenesis and anti-inflammatory activity of CEFFE. The existence of various growth factors in the CE FFE can explain the influence of the growth factors on the functions of epidermal cells, endothelial cells, fibroblasts and macrophages. CEFFEE may be used as a therapeutic drug for treating chronic wounds of diabetic patients, and is expected to improve the overall prognosis of the diabetic patients and improve the life quality of the patients.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

This invention discloses a method for constructing a type 2 diabetes mouse model combining artificial intelligence prediction and multi-target knockout. The method involves acquiring and standardizing multi-omics data and baseline phenotypic data of mice to form a standardized modeling dataset; constructing an interaction map covering pancreatic β-cell function based on this data; selecting target target combinations and target phenotypic prediction results; generating construction instructions and submitting them to a controlled facility for multi-gene knockout modification to obtain modified mice and modification receipts; obtaining measured phenotypic data of the modified mice based on the modification receipts; comparing this data with the target phenotypic prediction results to generate phenotypic deviation metrics and phenotypic determination results; and registering the target target combinations, prediction results, measured phenotypic data, and modification receipts when the phenotypic determination results are satisfactory to form a type 2 diabetes composite mouse model. This invention achieves closed-loop optimization of AI-driven multi-target genetic modification, improving the efficiency and accuracy of constructing animal models of complex metabolic diseases.

The invention discloses a pentapeptide YP5 with a function of relieving diabetic kidney injury as well as a preparation method and application of the pentapeptide YP5, and belongs to the technical field of biology. The pentapeptide YP5 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is YVAAP, and the pentapeptide YP5 has the function of relieving the diabetic kidney injury, can remarkably reduce the content of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing the medicine for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of the FER1L6 gene in the prevention and treatment of diabetes. In this application, the expression of GLUT4 is increased by inhibiting the expression of FER1L6, thereby improving the related physiological metabolism in diabetic organisms. This physiological metabolism includes glucose uptake, lipid metabolism, and oxidative stress damage. Experimental results show that FER1L6 is highly expressed in type 2 diabetic mice and insulin-resistant HepG2 cells; reducing FER1L6 expression significantly increases GLUT4 expression, ultimately improving lipid metabolism and oxidative stress damage in diabetic mice, while also enhancing cellular glucose uptake. Therefore, it can be concluded that FER1L6 is a good regulatory target for the prevention and treatment of type 2 diabetes based on the GLUT4 pathway. Based on this target, new technical approaches can be provided for the prevention and control of type 2 diabetes.

The invention discloses a type 2 diabetes mellitus mouse model construction method combining artificial intelligence prediction and multi-target knockout. Acquiring and standardizing mouse multi-omics data and phenotype baseline data to form a standardized modeling data set; constructing an interaction map covering the functions of the pancreatic beta cells on the basis of the data; screening to obtain a target combination and a target phenotype prediction result, generating a construction instruction, and submitting the construction instruction to a controlled facility to execute multi-gene knockout transformation, so as to obtain a transformed mouse and a transformation receipt; acquiring actual measurement phenotype data of the transformed mouse based on the transformation receipt, and comparing the actual measurement phenotype data with a target phenotype prediction result to generate phenotype deviation measurement and a phenotype judgment result; and when the phenotype determination result is satisfied, registering the target combination, the prediction result, the actually measured phenotype data and the transformation receipt to form the type-2 diabetes mellitus composite mouse model. According to the method, AI-driven multi-target genetic modification closed-loop optimization is realized, and the efficiency and accuracy of complex metabolic disease animal model construction are improved.

The invention provides application of plant hormone mitochondrial acid 5 in preparation of a medicine for treating myocardial injury caused by diabetes, and relates to the technical field of biological medicine. In the aspects of blood sugar and blood fat, the MA-5 reduces the blood sugar and blood fat levels of the mouse with the type 2 diabetes mellitus; in the aspect of cardiac injury involved by diabetes, MA-5 inhibits cardiac tissue fibrosis, improves mitochondrial injury, inhibits oxidative stress and reduces ROS (reactive oxygen species) generation. The MA-5 has the effects of stably reducing blood glucose and protecting diabetic cardiomyopathy. The composition is simple and clear; the taking is convenient; the price is low, and the like. Compared with the existing medicines for treating diabetes and diabetic cardiomyopathy, the chemical components of the MA-5 are simple and clear, the action mechanism of the MA-5 is easier to clarify in pharmacological research, and the quality of the medicines is easier to control in production. According to the application, a powerful experimental basis and a theoretical basis are provided for preventing and treating the type 2 diabetes mellitus and myocardial complications of the type 2 diabetes mellitus by the MA-5.